Top Page
Orthocell Ltd
(Sydney:OCC)
Orthocell Ltd (OCC) vs. iShares MSCI Australia ETF (EWA)
Orthocell Ltd Business Overview & Revenue Model
Orthocell Ltd Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.41M | 7.55M | 5.32M | 4.24M | 1.53M | 1.02M |
| Gross Profit | 3.50M | 4.80M | 3.69M | 3.06M | 832.52K | 299.88K |
| EBITDA | -15.31M | -13.43M | -11.68M | -10.34M | -11.52M | -11.67M |
| Net Income | -12.48M | -8.57M | -7.18M | -6.25M | -9.11M | -9.04M |
Balance Sheet | ||||||
| Total Assets | 59.80M | 35.24M | 26.62M | 29.61M | 37.90M | 19.33M |
| Cash, Cash Equivalents and Short-Term Investments | 44.37M | 28.62M | 20.61M | 24.82M | 11.02M | 16.33M |
| Total Debt | 835.79K | 576.89K | 689.69K | 562.30K | 507.56K | 621.72K |
| Total Liabilities | 18.64M | 20.67M | 22.08M | 23.46M | 27.99M | 2.46M |
| Stockholders Equity | 41.16M | 14.57M | 4.53M | 6.15M | 9.90M | 16.87M |
Cash Flow | ||||||
| Free Cash Flow | -12.21M | -9.04M | -7.45M | 13.96M | -6.80M | -4.82M |
| Operating Cash Flow | -12.05M | -8.68M | -6.51M | 14.59M | -6.26M | -4.63M |
| Investing Cash Flow | -42.26M | -359.06K | -942.02K | -631.56K | -535.02K | -188.52K |
| Financing Cash Flow | 30.84M | 17.05M | 3.24M | -164.61K | 1.49M | 709.15K |
Orthocell Ltd Technical Analysis
Orthocell Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$156.16M | -5.99 | ― | ― | ― | 0.66% | |
52 Neutral | AU$98.99M | -11.71 | -47.98% | ― | 700.00% | 26.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$567.38M | -6.72 | -35.86% | ― | ― | -19.21% | |
48 Neutral | AU$285.19M | -17.46 | -83.97% | ― | 1271.12% | 36.87% | |
46 Neutral | AU$114.21M | -2.91 | -81.03% | ― | -20.79% | 73.98% | |
41 Neutral | AU$257.74M | -18.66 | -89.70% | ― | 42.05% | -0.84% |
Orthocell Ltd Corporate Events
Orthocell has reported record first-half FY26 revenue of $6.2 million, up 48% year-on-year, driven by rising adoption of its Striate+ and Remplir products and improved gross margins of 55%. The company remains loss-making, with a $5.2 million net loss after tax reflecting heavy investment in U.S. commercial infrastructure, automation and systems to support its global scale-up.
The U.S. launch of Remplir is advancing, with approvals secured in 45 states and growing hospital account penetration, while national distribution in Canada and new channels in Hong Kong bolster its international footprint. Orthocell is also targeting nerve-sparing prostate surgery and preparing EU and U.K. market entry, supported by a strong $49.4 million cash position and portfolio expansion via PearlBone, which together position the company for broader market access and long-term growth.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has issued a US market and operational update presentation, but the released text consists solely of standard legal and confidentiality disclaimers typically accompanying investor or corporate communications. The document outlines that the material is not an offer or solicitation for securities, must not be relied upon as comprehensive investment advice, is confidential and restricted in its use and distribution, and that any forward-looking statements are subject to significant risks and uncertainties, underscoring limited liability and no obligation to update such statements beyond legal requirements.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited will host an investor webinar on 2 February 2026 to provide an operational update, with a particular focus on the rollout of its Remplir nerve repair device in the United States. The briefing, led by the company’s chairman and chief executive, underscores the strategic importance of the US market to Orthocell’s growth, following recent regulatory clearances and the establishment of a specialist US distributor network that has already generated initial sales, and will give investors and stakeholders further insight into how its expanding product portfolio and regulatory progress are shaping its commercial trajectory in regenerative medicine.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell reported its seventh consecutive quarter of record revenue, posting $3.2 million for the December 2025 quarter, up 45% year on year, driven by accelerating adoption of its Remplir nerve repair device and initial US sales. Backed by $49.4 million in cash following a heavily supported $30 million capital raising, the company is ramping up global commercialisation of Remplir with a distributor network now covering more than 25 US states, early traction in Canada and Hong Kong, and a regulatory application lodged for entry into the sizeable EU and UK nerve repair markets; it also secured global distribution rights to PearlBone bone regeneration technology and is building a new commercial opportunity in nerve-sparing prostate cancer surgery that could expand its US addressable market to about US$2 billion.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell has executed a binding agreement with Marine Biomedical Pty Ltd, lifting its equity stake from 1.72% to 11.7% for AU$1.05 million and securing a first right of refusal over global distribution rights for PearlBone, a next-generation bone substitute made from sustainably sourced pearl shells, as well as future bone repair products. The deal converts a prior memorandum into a formal strategic partnership, broadening Orthocell’s offering into bone regeneration alongside its existing nerve and tendon repair technologies and positioning it as a multi-tissue regenerative medicine provider targeting complex trauma and reconstructive procedures. With Marine Biomedical progressing PearlBone toward a U.S. FDA 510(k) submission and potential entry into the US$1.6 billion global bone substitute market, Orthocell aims to capitalise on its U.S. distribution network, supported by robust cash reserves of $49.4 million to fund ongoing commercial expansion.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell reported record quarterly revenue of $3.2 million for the December 2025 quarter, its seventh consecutive quarter of record sales, driven by strong Remplir nerve repair product uptake in existing markets and initial U.S. sales. The company’s hybrid U.S. market entry strategy—combining specialist distributors with internal field leadership—is gaining traction, with distributor coverage now spanning more than 25 states, 23 hospital Value Analysis Committee approvals, and multiple medical education events completed, while Canadian market entry is underway. Supported by $49.4 million in cash reserves, no debt and an expected R&D tax refund, Orthocell is well positioned to accelerate Remplir adoption and pursue a step-change in revenue as it scales across North America.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell has disclosed a change in the interests of managing director Paul Anderson, who holds securities both directly and indirectly through family-related entities including the Elwing Superannuation Fund and the Elwing Family Trust. The filing shows that 126,580 short-term performance rights expiring in November 2027 have vested and been exercised into an equivalent number of ordinary shares at no cash consideration, reflecting the satisfaction of preset performance conditions and increasing Anderson’s direct equity exposure while reducing his performance rights balance; the move underscores ongoing alignment between executive remuneration and shareholder outcomes but does not involve any on-market trading or changes to contractual interests.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has issued 217,742 fully paid ordinary shares for nil consideration following the exercise of an equivalent number of short‑term performance rights expiring in November 2027, and has confirmed that the issue was conducted without a disclosure document under the relevant Corporations Act provisions. The company stated it is compliant with its continuous disclosure and financial reporting obligations and that there is no excluded information to disclose, signalling a routine capital structure adjustment with no additional material information flagged for investors at this time.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has applied to the ASX for quotation of 217,742 new fully paid ordinary shares under its ticker OCC. The additional securities, issued on 22 December 2025 following the exercise or conversion of existing options or other convertible instruments, will modestly increase the company’s free float and share capital, offering existing holders greater liquidity while signalling continued utilisation of equity-based funding mechanisms.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has achieved a milestone in its U.S. commercial rollout of Remplir™, with 100 units sold in the $1.6 billion U.S. nerve repair market. This accomplishment reflects growing adoption fueled by a robust medical education campaign and a specialized distributor network. The company’s early success, including significant hospital VAC approvals, positions Remplir™ for future growth in both the U.S. and Canada, targeting a combined addressable market of $3.5 billion. Leveraging strong distribution frameworks and a debt-free financial position, Orthocell aims to accelerate its global market expansion.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has submitted a regulatory application to the British Standards Institution for approval to distribute its nerve repair product, Remplir™, in the EU and UK markets, which represent a combined market size of US$750 million. The company expects to receive the necessary certifications by the third quarter of 2026, enabling it to expand its global market presence. The application is supported by strong clinical evidence, including an 81.1% treatment success rate from recent studies, positioning Remplir™ as a key player in nerve repair surgery. Orthocell’s strategy includes forming a panel of key opinion leaders and utilizing in-country distributors to drive market adoption, supported by a robust financial position with approximately $50 million in cash.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has achieved a significant milestone with the first commercial sales of its product, Remplir™, in Hong Kong, marking a crucial step in its Asian growth strategy. This expansion is part of Orthocell’s broader global commercialization plan, which includes sales in multiple countries and aims to establish Remplir as a standard in peripheral nerve repair. The company’s strategic entry into Hong Kong serves as a gateway to the Greater Bay Area, a major healthcare market, and is supported by partnerships with local distributors. With substantial financial resources and no debt, Orthocell is well-positioned to drive product adoption and revenue growth.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced a change in the director’s interest, specifically regarding Paul Anderson, who has been issued 52,078 Short-Term Performance Rights following shareholder approval. This adjustment in director’s interest reflects the company’s ongoing commitment to aligning management incentives with shareholder interests, potentially impacting the company’s governance and stakeholder confidence.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited announced the issuance of 52,078 performance rights set to expire in November 2028, as part of an employee incentive scheme. This move is aimed at motivating and retaining talent within the company, potentially enhancing its operational capabilities and competitive positioning in the biotechnology sector.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.